佐剂流感疫苗在老年人照护中的重要性与价值——欧洲视角下对近期真实世界数据文献的系统综述
该系统综述检索2020年2月7日至2021年9月6日发表的真实世界研究,比较佐剂流感疫苗(aTIV/aQIV)与标准剂量(TIV/QIV)及高剂量(TIV-HD/QIV-HD)疫苗在≥65岁人群中的相对疫苗效力。作者认为佐剂和高剂量疫苗均是老年人接种规划中优于常规标准剂量疫苗的有效选择。
要点
- aTIV较TIV和QIV显著降低流感相关结局,rVE范围7.1%至36.3%。
- aTIV与TIV-HD效果相似,部分分析中aTIV优于TIV-HD。
核心结论
- 研究提示佐剂疫苗和高剂量疫苗均是老年人接种规划中优于常规标准剂量疫苗的有效选择。
研究设计与样本
- 在Embase和MEDLINE系统检索2020年2月7日至2021年9月6日发表的随机对照试验、观察性研究和系统综述。
- 纳入研究采用Cochrane偏倚风险工具、ROBINS-I或AMSTAR 2进行评价。
主要发现
- 9项分析发现aTIV较TIV和QIV显著更有效降低流感相关结局,aTIV vs TIV的rVE为7.5%至25.6%,aTIV vs QIV的rVE为7.1%至36.3%。
- 7项分析发现aTIV与TIV-HD在减少流感相关就医、住院和住院/急诊就诊方面效果相似。
- 3项分析发现aTIV较TIV-HD显著更有效降低流感相关就医和门诊就诊,rVE为6.6%至16.6%。
- 纳入研究的偏倚风险为中至高度。
临床怎么用
- 作者认为佐剂疫苗和高剂量疫苗均是老年人接种规划中优于常规标准剂量疫苗的有效选择。
局限性
- 纳入研究的偏倚风险为中至高度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an urgent need for improved influenza vaccines especially for older adults due to the presence of immunosenescence. It is therefore highly relevant to compare enhanced influenza vaccines with traditional influenza vaccines with respect to their effectiveness. OBJECTIVE: To compare vaccine efficacy and effectiveness of adjuvanted influenza vaccines (aTIV/aQIV) vs. non-adjuvanted standard-dose (TIV/QIV) and high-dose (TIV-HD/QIV-HD) influenza vaccines regarding influenza-related outcomes in older adults, complementing findings from the European Centre for Disease Prevention and Control (ECDC)'s systematic review of enhanced seasonal influenza vaccines from February 2020. METHODS: A systematic literature search was conducted in Embase and MEDLINE to identify randomised controlled trials, observational studies and systematic reviews, published since ECDC's systematic review (between 7 February 2020 and 6 September 2021). Included studies were appraised with either the Cochrane Risk of Bias tool, ROBINS-I or AMSTAR 2. RESULTS: Eleven analyses from nine real-world evidence (RWE) studies comprising ∼53 million participants and assessing the relative vaccine effectiveness (rVE) of aTIV vs. TIV, QIV and/or TIV-HD in adults aged ≥65 years over the 2006/07-2008/09 and 2011/12-2019/20 influenza seasons were identified. Nine analyses found that aTIV was significantly more effective than TIV and QIV in reducing influenza-related outcomes by clinical setting and suspected influenza outbreaks (rVE ranging from 7.5% to 25.6% for aTIV vs. TIV and 7.1% to 36.3% for aTIV vs. QIV). Seven analyses found similar effectiveness of aTIV vs. TIV-HD in reducing influenza-related medical encounters, inpatient stays and hospitalisations/emergency room visits. In three analyses, aTIV was significantly more effective than TIV-HD in reducing influenza-related medical encounters and office visits (rVE ranging from 6.6% to 16.6%). Risk of bias of identified studies was moderate to high. CONCLUSIONS: Our study suggests that both adjuvanted and high-dose vaccines are effective alternatives for vaccination programmes in older adults and preferable over conventional standard-dose vaccines.
引用
- Gärtner BC, Weinke T, Wahle K, et al. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data. Vaccine. 2022. PMID: 35459556. doi:10.1016/j.vaccine.2022.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。